A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

NCT03312530 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Cobimetinib
DRUG: Venetoclax
DRUG: Atezolizumab

Sponsor

Hoffmann-La Roche